Table 3 Summary of disease characteristics and PARP inhibitor treatment characteristics for BRCAm patients in receipt of a PARP inhibitor (n = 9).
Disease stage | PARP inhibitor received | Number of cycles dispensed | Days on PARP inhibitor | Reason for discontinuation | Age at date of initiation on PARP inhibitor |
|---|---|---|---|---|---|
Post third-line chemotherapy, platinum sensitive | Olaparib | 8 | 210 | Disease progression | 59 |
Post third-line chemotherapy, platinum sensitive | Olaparib | 7* | 206 | Disease progression | 52 |
Post second-line chemotherapy, platinum sensitive^ | Niraparib | 4* | 181 | Disease progression | 66 |
Post third-line chemotherapy, platinum sensitive | Olaparib | 1 | 1 | Disease progression | 57 |
Post third-line chemotherapy, platinum sensitive | Olaparib | 2 | 35 | Disease progression | 63 |
Post third-line chemotherapy, platinum sensitive | Olaparib | 1 (ongoing) | Ongoing | N/A - ongoing | 47 |
Post second-line chemotherapy, platinum sensitive^ | Niraparib | 3* | 147 | Disease progression | 52 |
Post second-line chemotherapy, platinum resistant^ | Rucaparib | 2* (ongoing) | Ongoing | N/A - ongoing | 77 |
Post third-line chemotherapy, platinum sensitive | Olaparib | 1* | <7 | Unacceptable toxicities | 80 |
